<DOC>
	<DOC>NCT02321930</DOC>
	<brief_summary>This proposal will evaluate if musculoskeletal ultrasound (MSUS) measures or multi-biomarker disease activity (MBDA) improve in patients treated with tofacitinib over 3 months, and whether early MSUS measures/MBDA can predict response to therapy.</brief_summary>
	<brief_title>Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>1. Patient must meet 1987 ACR criteria 2. Age &gt; 18 years of age 3. Baseline DAS28/ESR&gt;=3.2 4. Stable concomitant DMARDs 5. Stable prednisone &lt;10mg or equivalent 6. Power Doppler score of &gt;=10</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Musculoskeletal Ultrasound</keyword>
	<keyword>Tofacitinib</keyword>
	<keyword>biomarker</keyword>
</DOC>